Intriguingly, among patients with advanced‐stage melanoma treated with ipilimumab, research has revealed that individuals demonstrating NY‐ESO‐1 seropositivity alongside the presence of CD8+ T cells experienced more frequent clinical benefits and enhanced survival compared to those lacking detectable CD8+ T‐cell responses.53 This evidence concerns the gene CTAG1B and melanoma.